Temporary loss of consciousness during cetuximab treatment of a patient with metastatic colon cancer: a case report.

BACKGROUND: Anti-epidermal growth factor receptor (EGFR) antibody is widely used for the treatment of patients with metastatic colorectal cancer. Hypomagnesemia is a comparatively frequent adverse event of this drug, which is likely overlooked because it occurs later in treatment without symptoms. Furthermore, hypomagnesemia and hypomagnesemia-induced corrected QT (QTc) prolongation may lead to loss of consciousness (LOC), the onset of which is not generally considered associated with the treatment of anti-EGFR antibody because of its rare occurrence. Here, we present a colorectal cancer patient treated with anti-EGFR antibody, who suffered LOC during treatment while severe hypomagnesemia or QTc prolongation was not observed. CASE PRESENTATION: A 69-year-old man with metastatic colon cancer was treated with cetuximab (anti-EGFR antibody) plus irinotecan as third-line chemotherapy. His serum magnesium level gradually decreased, and grade 2 hypomagnesemia (a serum magnesium level of 0.9 mg/dL) was observed at the 12th administration of cetuximab. In light of this development, intravenous supplementation of 20 mEq magnesium sulfate began with careful blood monitoring despite the lack of clinical symptoms. Electrocardiogram (ECG) showed prolonged QT or corrected QT (QTc) intervals (grade 1). His serum magnesium level remained at 0.9 mg/dL, and no hypomagnesemia symptoms were observed by the 17th administration of cetuximab. After the treatment, however, he suddenly lost consciousness without symptoms related to infusion or allergic reactions. Circulatory collapse following dermatological reactions and respiratory events were not evident. Intravenous supplementation of magnesium sulfate was administered again. He awakened 2 min after the onset of temporary LOC without any other symptoms related to hypomagnesemia, such as lethargy, tremor, tetany, and seizures. No other etiology outside of the low level of serum magnesium was confirmed in further examinations. Cetuximab was discontinued, and his serum magnesium level returned to a level within the normal range after 6 weeks. Because of tumor progression, regorafenib and TAS-102 (trifluridine tipiracil hydrochloride) were introduced sequentially for 6 months. Five months after the final treatment of TAS-102, he died of his primary disease, which reflected a survival period of 4 years and 6 months since the beginning of treatment. CONCLUSIONS: This case report reminds clinicians that LOC can be induced without severe hypomagnesemia or QTc prolongation, during anti-EGFR antibody treatment for metastatic colorectal cancer even while under carefully monitored magnesium supplementation.

Effectiveness of preoperative chemotherapy for far advanced gastric cancer.

We herein report a case in which preoperative chemotherapy with cisplatin and 5-fluorouracil was found to effectively treat far advanced gastric cancer invading the pancreas forming a huge mass with regional and distant lymph node metastases. As a result of this treatment regimen, a potentially curative resection was performed which led to a substantially increased survival. The patient was treated with 10 mg of cisplatin and 1000 mg of 5-fluouracil each day preoperatively. After the continuous administration of these drugs for 28 days, the findings of extensive pancreas invasion and lymph node metastases dramatically disappeared. The tumor could be curatively resected by a total gastrectomy with lymph nodes dissection, combined with a distal pancreatectomy and splenectomy. A histological study of a resected specimen showed some cancer cell infiltration remaining within the muscularis propria with fibrous change. There was no evidence of either pancreas invasion or lymph node metastasis. As a result, postoperative adjuvant chemotherapy was performed, 14 months later lymph nodes recurrence was detected and the patient died 20 months after surgery. Our findings suggest that preoperative chemotherapy may thus be effective for the treatment of gastric cancer by both reducing the tumor burden and prolonging survival.

EFEITO DA ADUBAÇÃO ORGÂNICA NA PRODUÇÃO DE BIOMASSA EM QUEBRA-PEDRA (Phyllanthus stipulatus, EUPHORBIACEAE) EM MANAUS, AMAZONAS, BRASIL

Quebra-pedra (Phyllanthus stipulatus (Raf.) Webster, Euphorbiaceae) is a popular remedy used to reduce uric acid in blood and to facilite the elimination of kidney stones. The research was carried out at the Vegetable Crops Experiment Station of the National Institute for Amazonian Research, in Manaus, Amazonas, Brazil, using seeds of a local wild population. A split-plot design was used, where the main plots were the natural environment and 50% shade, the subplots were constituted by doses of 0,2,4,6, 8 and 10 kg of organic compost (OC)/m2 and contained 20 plants in 1 m2. The following characters of the 6 useful plants per subplot were evaluated: stalk diameter at soil level, plant height, root, stalk, branch and leaf biomass (fresh and dry). No significant differences among environments were found for total plant biomass (63.1 g vs 62.3 g fresh wt, 26.6 g vs 25.6 g dry wt, respectively), but were found for height (70.0 cm in sun light vs 96.2 cm in shade) and, consequendy, for stalk biomass (5.1 and 5.7 g dry wt, respectively). Quebra-pedra responds to organic manure, both in total biomass and in all of its components, with an increment of 43% in total biomass between the minimum and maximum treatment, but the benefit/cost ratio suggests that 4 kg of OC/m2 is the maximum amount that is economically viable in the soil used. Total biomass is composed of 17.2% root, 22.3% stalk, 23.1% branches and 37.4% leaves. Plant growth demands considerable potassium but little phosphorous, magnesium or micronutrients.

O quebra-pedra (Phyllanthus stipulatus (Raf.) Webster, Euphorbiaceae) é um importante remédio popular usado para reduzir o ácido urico no sangue e facilitar a eliminação de cálculos renais. Para avaliar a produção de biomassa dessa espécie utilizou-se sementes de populações naturais num experimento realizado em Manaus, AM. Adotou-se um delineamento experimental de parcelas subdivididas, onde as parcelas foram: (a) o ambiente natural e (b) o ambiente com tela plástica sombrite com 50% de luminosidade, e as subparcelas constituídas por dosagens de 0,2,4,6,8 e 10 kg de composto orgânico/ m2. Não foram encontradas diferenças significativas entre os ambientes na biomassa total das plantas (63,1 g vs 62,3 g fresca e 26,6 g vs 25,6 g seca), embora tivessem sido encontradas para a altura (70,0 cm a pleno sol vs 96,2 cm sombra) e, conseqüentemente, para a biomassa do caule (5,lg vs 5,7 g seca, respectivemente). O quebra-pedra responde bem a adubação orgânica, tanto na biomassa total, como em todas as partes da planta. A melhor resposta, em termos de rendimento, se deu sob o efeito de 10 kg de CO/m2 incorporado ao solo ( 1,26 kg/m2 de biomassa fresca e 0,55 kg/m2 de biomassa seca). Em comparação com a testemunha, este tratamento produziu 43% mais biomassa seca total. No entanto, a razão benefício/ custo sugere que 4 kg de CO/m2 é a quantidade máxima que é economicamente viável no solo usado. A biomassa total é composta de 17,2% de raízes, 22,3% de caules, 23,1% de galhos e 37,4% de folhas. O crescimento das plantas exige muito potássio e pouco fósforo, magnésio e micronutrientes.